
Sign up to save your podcasts
Or


In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets from 2024.
Did Merck hold on to its 2023 crown? And did any new faces crack this year’s list? Listen to find out!
To learn more about the topics in this episode:
This week's episode is brought to you by Cencora.
See omnystudio.com/listener for privacy information.
By Fierce Life Sciences4.1
1212 ratings
In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets from 2024.
Did Merck hold on to its 2023 crown? And did any new faces crack this year’s list? Listen to find out!
To learn more about the topics in this episode:
This week's episode is brought to you by Cencora.
See omnystudio.com/listener for privacy information.

3,231 Listeners

1,727 Listeners

4,383 Listeners

2,189 Listeners

403 Listeners

1,989 Listeners

350 Listeners

1,650 Listeners

171 Listeners

101 Listeners

3,986 Listeners

1,445 Listeners

337 Listeners

34 Listeners

170 Listeners